These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29374782)

  • 1. Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.
    Cirac A; Stützle S; Dieckmeyer M; Adhikary D; Moosmann A; Körber N; Bauer T; Witter K; Delecluse HJ; Behrends U; Mautner J
    Cancer Immunol Immunother; 2018 Apr; 67(4):663-674. PubMed ID: 29374782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoinformatic Analysis Reveals Antigenic Heterogeneity of Epstein-Barr Virus Is Immune-Driven.
    Cirac A; Poirey R; Dieckmeyer M; Witter K; Delecluse HJ; Behrends U; Mautner J
    Front Immunol; 2021; 12():796379. PubMed ID: 34975903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection.
    Palser AL; Grayson NE; White RE; Corton C; Correia S; Ba Abdullah MM; Watson SJ; Cotten M; Arrand JR; Murray PG; Allday MJ; Rickinson AB; Young LS; Farrell PJ; Kellam P
    J Virol; 2015 May; 89(10):5222-37. PubMed ID: 25787276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.
    Brooks JM; Croom-Carter DS; Leese AM; Tierney RJ; Habeshaw G; Rickinson AB
    J Virol; 2000 Feb; 74(4):1801-9. PubMed ID: 10644353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Fogg MH; Wirth LJ; Posner M; Wang F
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response.
    Bell MJ; Brennan R; Miles JJ; Moss DJ; Burrows JM; Burrows SR
    J Infect Dis; 2008 Jun; 197(11):1594-7. PubMed ID: 18419576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
    Midgley RS; Bell AI; Yao QY; Croom-Carter D; Hislop AD; Whitney BM; Chan AT; Johnson PJ; Rickinson AB
    J Virol; 2003 Nov; 77(21):11507-16. PubMed ID: 14557636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
    Lin N; Ku W; Song Y; Zhu J; Lu Z
    Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies.
    Sim AC; Too CT; Oo MZ; Lai J; Eio MY; Song Z; Srinivasan N; Tan DA; Pang SW; Gan SU; Lee KO; Loh TK; Chen J; Chan SH; MacAry PA
    Sci Rep; 2013 Nov; 3():3232. PubMed ID: 24240815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
    Ning RJ; Xu XQ; Chan KH; Chiang AK
    Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.
    Rist MJ; Neller MA; Burrows JM; Burrows SR
    J Virol; 2015 Jan; 89(1):703-12. PubMed ID: 25355876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection.
    Woodberry T; Suscovich TJ; Henry LM; Davis JK; Frahm N; Walker BD; Scadden DT; Wang F; Brander C
    J Infect Dis; 2005 Nov; 192(9):1513-24. PubMed ID: 16206065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
    PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunodominant CD8 T cell response to Epstein-Barr virus.
    Houssaint E; Saulquin X; Scotet E; Bonneville M
    Biomed Pharmacother; 2001 Sep; 55(7):373-80. PubMed ID: 11669500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.